These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 35383164)

  • 1. A booster with SARS-CoV-2 vaccines: protection against Omicron infection.
    Hu Y; Sun Q
    Signal Transduct Target Ther; 2022 Apr; 7(1):115. PubMed ID: 35383164
    [No Abstract]   [Full Text] [Related]  

  • 2. Generation of neutralizing antibodies against Omicron, Gamma and Delta SARS-CoV-2 variants following CoronaVac vaccination.
    Silva ARD; Villas-Boas LS; Tozetto-Mendoza TR; Honorato L; Paula A; Witkin SS; Mendes-Correa MC
    Rev Inst Med Trop Sao Paulo; 2022; 64():e19. PubMed ID: 35239863
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Homologous or heterologous booster of inactivated vaccine reduces SARS-CoV-2 Omicron variant escape from neutralizing antibodies.
    Wang X; Zhao X; Song J; Wu J; Zhu Y; Li M; Cui Y; Chen Y; Yang L; Liu J; Zhu H; Jiang S; Wang P
    Emerg Microbes Infect; 2022 Dec; 11(1):477-481. PubMed ID: 35034583
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A nasal omicron vaccine booster elicits potent neutralizing antibody response against emerging SARS-CoV-2 variants.
    Lam JY; Ng YY; Yuen CK; Wong WM; Yuen KY; Kok KH
    Emerg Microbes Infect; 2022 Dec; 11(1):964-967. PubMed ID: 35275039
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Omicron variant showed lower neutralizing sensitivity than other SARS-CoV-2 variants to immune sera elicited by vaccines after boost.
    Ai J; Zhang H; Zhang Y; Lin K; Zhang Y; Wu J; Wan Y; Huang Y; Song J; Fu Z; Wang H; Guo J; Jiang N; Fan M; Zhou Y; Zhao Y; Zhang Q; Liu Q; Lv J; Li P; Qiu C; Zhang W
    Emerg Microbes Infect; 2022 Dec; 11(1):337-343. PubMed ID: 34935594
    [No Abstract]   [Full Text] [Related]  

  • 6. Effectiveness of COVID-19 vaccines against Omicron variant.
    de Oliveira Campos DM; da Silva MK; Silva de Oliveira CB; Fulco UL; Nobre Oliveira JI
    Immunotherapy; 2022 Aug; 14(12):903-904. PubMed ID: 35787018
    [No Abstract]   [Full Text] [Related]  

  • 7. mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 Omicron variant.
    Gruell H; Vanshylla K; Tober-Lau P; Hillus D; Schommers P; Lehmann C; Kurth F; Sander LE; Klein F
    Nat Med; 2022 Mar; 28(3):477-480. PubMed ID: 35046572
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Booster BNT162b2 COVID-19 Vaccination Increases Neutralizing Antibody Titers Against the SARS-CoV-2 Omicron Variant in Both Young and Elderly Adults.
    Um J; Choi YY; Kim G; Kim MK; Lee KS; Sung HK; Kim BC; Lee YK; Jang HC; Bang JH; Chung KH; Oh MD; Park JS; Jeon J
    J Korean Med Sci; 2022 Mar; 37(9):e70. PubMed ID: 35257525
    [TBL] [Abstract][Full Text] [Related]  

  • 9. No correlation of neutralizing antibody titers against the Omicron variant after a booster dose of COVID-19 vaccines with subsequent breakthrough Omicron infections among healthcare workers.
    Lee J; Park S; Kim JY; Lim SY; Chang E; Bae S; Jung J; Kim MJ; Chong YP; Lee SO; Choi SH; Kim YS; Lee N; Shum D; Kim S; Jee Y; Kim SH
    J Infect; 2022 Dec; 85(6):e177-e180. PubMed ID: 36223860
    [No Abstract]   [Full Text] [Related]  

  • 10. Effect of mRNA Vaccine Boosters against SARS-CoV-2 Omicron Infection in Qatar.
    Abu-Raddad LJ; Chemaitelly H; Ayoub HH; AlMukdad S; Yassine HM; Al-Khatib HA; Smatti MK; Tang P; Hasan MR; Coyle P; Al-Kanaani Z; Al-Kuwari E; Jeremijenko A; Kaleeckal AH; Latif AN; Shaik RM; Abdul-Rahim HF; Nasrallah GK; Al-Kuwari MG; Butt AA; Al-Romaihi HE; Al-Thani MH; Al-Khal A; Bertollini R
    N Engl J Med; 2022 May; 386(19):1804-1816. PubMed ID: 35263534
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Three doses of an inactivation-based COVID-19 vaccine induces cross-neutralizing immunity against the SARS CoV-2 Omicron variant.
    Yu X; Qi X; Cao Y; Li P; Lu L; Wang P; Feng Y; Yang J; Wei H; Guo L; Sun M; Liu Q; Lv J; Feng Y
    Emerg Microbes Infect; 2022 Dec; 11(1):749-752. PubMed ID: 35176972
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma Neutralization of the SARS-CoV-2 Omicron Variant.
    Schmidt F; Muecksch F; Weisblum Y; Da Silva J; Bednarski E; Cho A; Wang Z; Gaebler C; Caskey M; Nussenzweig MC; Hatziioannou T; Bieniasz PD
    N Engl J Med; 2022 Feb; 386(6):599-601. PubMed ID: 35030645
    [No Abstract]   [Full Text] [Related]  

  • 13. Omicron likely to weaken COVID vaccine protection.
    Callaway E
    Nature; 2021 Dec; 600(7889):367-368. PubMed ID: 34880488
    [No Abstract]   [Full Text] [Related]  

  • 14. Vaccines elicit highly conserved cellular immunity to SARS-CoV-2 Omicron.
    Liu J; Chandrashekar A; Sellers D; Barrett J; Jacob-Dolan C; Lifton M; McMahan K; Sciacca M; VanWyk H; Wu C; Yu J; Collier AY; Barouch DH
    Nature; 2022 Mar; 603(7901):493-496. PubMed ID: 35102312
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The emergence of SARS-CoV-2 variants threatens to decrease the efficacy of neutralizing antibodies and vaccines.
    Murano K; Guo Y; Siomi H
    Biochem Soc Trans; 2021 Dec; 49(6):2879-2890. PubMed ID: 34854887
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protein-based SARS-CoV-2 spike vaccine booster increases cross-neutralization against SARS-CoV-2 variants of concern in non-human primates.
    Pavot V; Berry C; Kishko M; Anosova NG; Huang D; Tibbitts T; Raillard A; Gautheron S; Gutzeit C; Koutsoukos M; Chicz RM; Lecouturier V
    Nat Commun; 2022 Mar; 13(1):1699. PubMed ID: 35361754
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low titers of SARS-CoV-2 neutralizing antibodies after first vaccination dose in cancer patients receiving checkpoint inhibitors.
    Terpos E; Zagouri F; Liontos M; Sklirou AD; Koutsoukos K; Markellos C; Briasoulis A; Papanagnou ED; Trougakos IP; Dimopoulos MA
    J Hematol Oncol; 2021 May; 14(1):86. PubMed ID: 34059088
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Omicron BA.1/1.1 SARS-CoV-2 Infection among Vaccinated Canadian Adults.
    Brown PE; Fu SH; Bansal A; Newcombe L; Colwill K; Mailhot G; Delgado-Brand M; Gingras AC; Slutsky AS; Pasic M; Companion J; Bogoch II; Morawski E; Lam T; Reid A; Jha P; ;
    N Engl J Med; 2022 Jun; 386(24):2337-2339. PubMed ID: 35584302
    [No Abstract]   [Full Text] [Related]  

  • 19. SARS-CoV-2 infection long time after full vaccination is related to a lack of neutralizing antibodies.
    Alidjinou EK; Gaillot O; Guigon A; Tinez C; Lazrek M; Bocket L; Engelmann I; Hober D
    Diagn Microbiol Infect Dis; 2022 Jan; 102(1):115565. PubMed ID: 34731684
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Perspective on the Roles of Adjuvants in Developing Highly Potent COVID-19 Vaccines.
    Zhang N; Li K; Liu Z; Nandakumar KS; Jiang S
    Viruses; 2022 Feb; 14(2):. PubMed ID: 35215980
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.